69 results about "Oral agents" patented technology

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention provides an oral dosage form for, and a therapeutically effective dose for the management and / or treatment of muscular dystrophy using Sitagliptin or its pharmaceutically acceptable salt, alone or in combination with other therapeutically effective agents.

The invention belongs to the technical field of pharmaceutical preparations, and provides a novel solution type nasal administration composition of quetiapine. In the provided composition, quetiapine is completely dissolved in the composition in the form of a solution, and is administered via the nose. The quetiapine solution type nasal preparation provided by the invention has especially useful pharmacokinetic and pharmacodynamic characteristics compared with oral dosage forms on the market. Compared with other disclosed nasal nano-emulsion forms, the nasal nano-emulsion still has surprising pharmacokinetic and pharmacodynamic characteristics, shows good clinical application prospects, and is expected to meet unsatisfied clinical requirements. On the basis, the invention also provides a further improved technical scheme of high saturated dissolution concentration and a further improved technical scheme of good chemical stability for preparing the quetiapine solution type nasal preparation.

The invention relates to the technical field of biological preparations, and discloses a periodontitis improving compound preparation containing fermented lactobacillus mucus and traditional Chinese medicine extracts, and the periodontitis improving compound preparation comprises the following raw materials: an oral preparation: fermented lactobacillus mucus CQPC202403 bacterial powder; the gel comprises scutellaria baicalensis, honeysuckle, salvia miltiorrhiza, liquorice and a hydrogel matrix; the preservation number of the lactobacillus mucus CQPC202403 in the China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO.31106, and the preservation date of the lactobacillus mucus CQPC202403 is June 27, 2024. The lactobacillus mucilaginosus adopted by the invention inhibits pathogenic bacteria through competitive rejection and immunoregulation; the traditional Chinese medicine extracts such as the radix scutellariae directly destroy bacterial pellicles, and the radix scutellariae and the traditional Chinese medicine extracts cooperate with each other, so that the antibacterial effect is enhanced on the premise of not causing drug resistance.

The application discloses a traditional Chinese medicine composition for benefiting qi and moistening dryness and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The composition is composed of 10-15 parts of Huangqi, 10-15 parts of Guizhi, 10-15 parts of Baishao, 10-15 parts of Dazao, 10-12 parts of Zhigancao, 5-8 parts of Mahuang and 6-9 parts of Shanyurou. The preparation method is to decoct with water, add or not add accessories after concentration, and prepare oral dosage forms such as decoction and granules. The application is based on the theory of 'yang qi is soft and can nourish tendons' and 'qi can produce saliva', takes the core principle of warming yang, benefiting qi, transforming qi and producing saliva, restores the qi transformation function of the human body, transpires and transmits water and liquid to the oral cavity, and is specially used for treating xerostomia of the type of yang deficiency and saliva not ascending and the type of qi deficiency and not spreading. Through clinical observation on 180 cases, the total effective rate of the application reaches 90.8%, which is obviously better than that of traditional yin nourishing treatment (48.3%). The composition is warm and not dry, and is used for treating diseases caused by yang deficiency and unstable defensive qi, such as body deficiency cold, allergic rhinitis, spontaneous sweating and the like.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

The present disclosure provides oral dosage forms comprising about 8.75% w / w deuruxolitinib phosphate, about 50% to about 60% w / w microcrystalline cellulose, about 25% to about 35% w / w lactose monohydrate, about 3% to about 6% w / w polyvinylpyrrolidone, about 2% to about 4% w / w hydroxypropyl cellulose, about 0.25% to about 0.75% w / w colloidal silicon dioxide, and about 0.25% to about 0.75% w / w magnesium stearate.

The invention relates to a pharmaceutical composition for treating or improving intestinal leakage and / or blood-brain barrier injury induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of pseudo-ginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be processed into pharmaceutically acceptable oral dosage forms such as granules, powder and the like; the pharmaceutical composition provided by the invention can improve expression of tight junction protein of vascular endothelial cells and intestinal epithelial cells, reduce the level of blood-brain barrier and intestinal barrier injury markers in blood, improve expression of tight junction protein in blood-brain barrier and intestinal barrier of sleep deprivation patients, reduce influence caused by sleep insufficiency and improve sleep deprivation effect. A new thought is provided for treating the injury problem caused by sleep insufficiency in traditional Chinese medicine.

The present invention discloses a heart-protective complex composition for improving the absorption rate of Coenzyme Q10 and a preparation method thereof, relating to the technical field of medicine and functional foods. The core active ingredients comprise Coenzyme Q10, Vitamin E, and black pepper extract within a specific mass ratio range. Pharmaceutically acceptable carriers and antioxidant synergists may also be combined to prepare various oral dosage forms. By constructing a ternary active component system with a specific ratio, the present invention achieves temporal synergy between absorption promotion and antioxidant regeneration in vivo, thereby solving the technical problems of low oral bioavailability and insufficient myocardial targeted accumulation of existing Coenzyme Q10 preparations. It significantly enhances the conversion efficiency of Coenzyme Q10 into the active form available to myocardial cells, and can be widely used in the preparation of drugs or functional foods for preventing or treating heart diseases.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

The invention discloses a traditional Chinese medicine composition for treating and preventing cardiovascular and cerebrovascular diseases and postoperative repair and recuperation based on classic famous prescription, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared by combining a prescription based on coptis and colla corii asini decoction, cassia twig decoction, cinnamomum cassia and aconitum carmichaeli decoction and poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, as well as poria cocos, cinnamomum cassia and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction, and poria cocos and aconitum carmichaeli decoction and poria cocos and In the formula, ligusticum wallichii and earthworm promote blood circulation to remove blood stasis, dredge collaterals and dissolve thrombus; hawthorn and lotus leaf are used for dissolving turbidity, lowering lipid and regulating blood fat and cholesterol; the poria cocos and the rhizoma alismatis are used for clearing damp and promoting diuresis. The whole formula has the effects of warming yang, dredging collaterals, nourishing yin and blood, promoting blood circulation to remove blood stasis, dissolving turbidity, reducing lipid, calming the heart, soothing the nerves and the like, can be used for treating cardiovascular and cerebrovascular diseases, conditioning dyslipidemia, preventing atherosclerosis and postoperative repair and nursing at the same time, is wide in application range and high in safety, can be prepared into various oral dosage forms, and has a good application prospect.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention provides a celecoxib cream and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the celecoxib cream comprises, by mass, 0.5%-2% of celecoxib, 1%-20% of an oily matrix, 1%-20% of an emulsifier, 0.1%-10% of a transdermal absorption enhancer, 1%-20% of a thickener, 2%-15% of a humectant, 0.1%-2% of a preservative, 0.1%-10% of a pH regulator, and the balance of deionized water. The prepared celecoxib cream is good in stability and high in bioavailability, and gastrointestinal reaction and oral first pass effect of a traditional oral dosage form are avoided. The celecoxib cream disclosed by the invention is also added with a transdermal absorption enhancer, so that medicine molecules can be helped to penetrate through a skin barrier and directly reach a focus part; the metabolism loss of the medicine on the skin surface can be reduced, more active ingredients enter blood circulation or deep tissues, the local treatment effect is enhanced, and the important clinical value is achieved.

The invention discloses an intestinal flora regulating composition for targeting drug-resistant enterobacter and application thereof, and relates to the technical field of biological medicines and microecological preparations, in particular to an intestinal flora regulating composition for targeting drug-resistant enterobacter and application thereof, the active ingredients comprise bacillus capable of interfering a drug-resistant enterobacter quorum sensing system, bacillus capable of interfering a drug-resistant enterobacter quorum sensing system, bacillus capable of interfering a drug-resistant enterobacter quorum sensing system, and bacillus capable of interfering the drug-resistant enterobacter quorum sensing system. The bacillus subtilis can be bacillus coagulans or bacillus subtilis; saccharomycetes capable of adsorbing the drug-resistant enterobacter and consuming necessary trace elements thereof, such as saccharomyces cerevisiae with optimized cell walls; the oligosaccharide mixture can be utilized by beneficial bacteria and can generate inhibitory products after being subjected to specific enzymolysis by drug-resistant enterobacter, and galactooligosaccharide, xylooligosaccharide and seaweed-derived oligosaccharide are mixed according to a specific proportion. The composition can be used for reducing the loading capacity of drug-resistant enterobacter in intestinal tracts of mammals, restoring the balance of intestinal flora and reducing the systemic infection risk. The preparation method comprises the step of mixing the active ingredients with a pharmaceutically or food acceptable carrier to prepare an oral dosage form.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to an herbal composition and method for a treatment and management of at least one of hypertension, hyperlipidemia, diabetes mellitus, and associated cardiovascular risk factors. The composition comprises standardized plant extracts derived from Rauvolfia serpentina, Hippophae rhamnoides seed, Citrullus lanatus seed, and Phyllanthus emblica fruit, in approximate weight proportions ranging from 20-40% for Rauvolfia serpentina, 20-40% for Hippophae rhamnoides, 10-30% for Citrullus lanatus, and 10-30% for Phyllanthus emblica. The invention also provides a method of preparing the composition involving harvesting, drying, grinding, extracting with selected solvents, concentrating, optionally fractionating, and formulating into oral dosage forms such as one of capsules, tablets, and powder sachets. The invention further includes methods for administering the composition to a subject in need thereof, optionally as an adjunct to conventional therapy.

The present invention discloses a pharmaceutical composition having activity of anti-tumor comprising a therapeutically effective amount of one or more compounds of formula I as the active ingredient, conventional pharmaceutically acceptable carriers, and one or more pharmaceutically acceptable acidic components, wherein said acidic component is selected from a group consisting of oleic acid, stearic acid, linolenic acid, fumaric acid, benzoic acid, tartaric acid, sorbic acid, lactic acid, citric acid, acetic acid and EDTA, wherein X is 0 or S; R is substituted or unsubstituted C3˜C10 straight or branched alkyl, C3˜C10 cycloalkyl, C3˜C10 straight or branched alkenyl or C3˜C10 straight or branched chain alkynyl; and if R has substituting group, said substituting group may be C1˜C6 alkyl, C1˜C6 alkoxy, C1˜C6 alkylthio group, C1˜C6 alkyl amino group, phenyl or phenyl substituted by halogen. Further, said composition may be made into all sorts of conventional dosage forms, in particular the oral dosage forms and topically administered transdermal dosage form. In addition, the invention discloses a method to use the composition for treatment of tumor.

The present application relates generally to dosage forms (e.g., oral dosage forms) and pharmaceutical compositions comprising a pharmaceutically active agent comprising telotristat or a pharmaceutically acceptable salt, solvate, or hydrate thereof; an enteric coating; and optionally one or more pharmaceutically acceptable excipients; and to methods of using the dosage forms and pharmaceutical compositions, and methods of making the dosage forms and pharmaceutical compositions.

The present invention relates to dry powder film coating compositions for use on oral dosage forms such as compressed tablets and other orally ingestible substrates. The film coating composition includes from 30 to 50% by weight of a water soluble polymer, from 25 to 50% by weight of calcium carbonate, and from 3 to 25% by weight of an opacity enhancer. Oral substrates such as tablets coated with the film coating composition are also disclosed, and have high opacity, improved color uniformity, and an overall excellent appearance.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The application belongs to the technical field of biological medicine, and specifically discloses application of seco-oxymatrine in preparation of an antidepressant, wherein the antidepressant further contains a pharmaceutically acceptable carrier; the antidepressant is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspension, an emulsion, a solution, a powder, a tablet, a granule and a capsule. When seco-oxymatrine is used as an effective component of the antidepressant, the depressive behavior of a LPS-induced depressive model mouse can be effectively improved.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

This invention discloses a traditional Chinese medicine composition for liver protection, its preparation method, and its application. By weight, the composition comprises 10-30 parts of kudzu root, 5-30 parts of Ganoderma lucidum, 10-30 parts of Hovenia dulcis fruit, 3-20 parts of licorice root, and 0.2-0.8 parts of turmeric extract. The formulation follows the principles of traditional Chinese medicine (TCM) theory of principal, assistant, and adjuvant herbs, with each ingredient synergistically enhancing its effect. It possesses both hangover-relieving and auxiliary protective effects against chemically induced liver damage, effectively reducing oxidative stress and lipid accumulation in the liver, protecting hepatocyte membranes, and promoting hepatocyte repair. The preparation process uses 30% ethanol reflux extraction, which is stable, controllable, safe, and easily industrialized. It can be formulated into various oral dosage forms, suitable for the daily maintenance needs of high-risk groups for liver damage, and has promising application prospects in the food, health food, and pharmaceutical fields.

The present disclosure provides for the treatment of pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a first therapeutically effective amount of a parenteral therapeutic agent for treating pulmonary hypertension, followed by administration of an oral dosage form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of the parenteral therapeutic agent is sufficient to allow for an increased amount of a subsequently administered orally administered therapeutic agent compared to a subject not previously treated with the parenteral therapeutic agent.

The present disclosure addresses this need by providing crystalline fine particle forms of 3-AP, methods for preparation and the treatment for solid tumors and hematological malignancies. In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or 3-APs, crystalline fine particle forms of 3-AP, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of 3-AP which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of 3-AP and excipients with improved stability. In additional aspects, the present disclosure provides novel methods of synthesizing novel crystalline fine particle form of 3-AP, preparing crystalline 3-AP particle delivery systems (PDS), and preparing novel final dosage forms (FDF) of crystalline fine particle 3-AP. In certain aspects, the present disclosure provides novel crystalline forms of fine particle 3-AP which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms.

The invention discloses a composition for promoting skeletal muscle injury regeneration and application thereof, and belongs to the technical field of medicines. In order to solve the technical problems that in the prior art, the skeletal muscle injury regeneration promotion effect of nutrients is insufficient, and the new application of eleutheroside B in the field is undefined, the invention provides a composition for promoting skeletal muscle injury regeneration, and the composition effectively shortens the regeneration time of skeletal muscle after chemical injury or mechanical injury and improves the skeletal muscle regeneration effect. The maturity of new muscle fibers is improved; the composition can be in oral dosage forms such as instant powder, oral liquid or tablets, can take effect on the day of injury, does not need local injection, is convenient to use, and is suitable for preparing functional food or formula food for special medical purposes for shortening the regeneration time of skeletal muscle after injury and improving the maturity of new muscle fibers. And a new technical scheme is provided for nutrition intervention of skeletal muscle injury.